Gilmore Girls, Parenthood and Zoey's Extraordinary Playlist star Lauren Graham spoke to Yahoo Canada about playing another hysterical kick ass mom in the new series The Mighty Ducks: Game Changers, which lands on Disney+ on March 26.
Gilmore Girls, Parenthood and Zoey's Extraordinary Playlist star Lauren Graham spoke to Yahoo Canada about playing another hysterical kick ass mom in the new series The Mighty Ducks: Game Changers, which lands on Disney+ on March 26.
From “Grey’s Anatomy” to “Bridgerton,” television producers Shonda Rhimes and Betsy Beers have strived to work with costume designers to visually create appealing wardrobes to help tell their character's story. Now, both women will be recognized for their successful collaborative efforts at the Costume Designers Guild Awards. The guild announced Monday that Rhimes and Beers will be honored with the Distinguished Collaborator Award.
The iPhone 13 series is most likely to include iPhone 13, iPhone 13 Mini, iPhone 13 Pro, and the iPhone 13 Pro Max.
British actress Nicola Charles alleges that two co-stars contacted Australia's immigration service.
Following a series of notable project enrollments, the International WELL Building Institute, the world’s leading organization focused on deploying people first places to advance a global culture of health, has seen Canada take a leading global role in the movement to advance health and well-being through better buildings, more vibrant communities and stronger organizations. With IWBI having more than 1.8 billion square feet of space in over 80 countries committed to achieving the WELL Health-Safety Rating or WELL Certification, IWBI has seen expansive growth over the past year. Canada’s leadership in the global adoption of WELL programs is notable, having over 100 million square feet enrolled, and many leading enterprises are in the process of certifying or rating their portfolios.
Khoros appoints April Downing as CFO and Sejal Amin as CTO to lead its global finance organization and development organization, respectively.
CALGARY, Alberta, April 12, 2021 (GLOBE NEWSWIRE) -- Total Energy Services Inc. (“Total Energy”) (TSX:TOT) will conduct a conference call and webcast following the release of its financial results for the three months ended March 31, 2021. The financial results will be released prior to the conference call. Daniel Halyk, President and CEO, will host the call. Open to:Shareholders and other interested persons Date:May 13, 2021 Time:9:00 a.m. (Mountain Time) Call:(800) 319-4610 or (416) 915-3239 A live webcast of the conference call will be accessible on Total Energy’s website at www.totalenergy.ca by selecting “Webcasts”. Shortly after the live webcast, an archived version will be available on Total Energy’s website. A recording of the conference call will also be available until June 12, 2021 by dialling (855) 669-9658, passcode 6598. Headquartered in Calgary, Alberta, Total Energy provides contract drilling services, rentals and transportation services, well servicing and compression and process equipment and service to the energy industry in North America, Australia and other international markets. The common shares of Total Energy are listed and trade on the TSX under the symbol “TOT”. For further information, please contact Yuliya Gorbach, Vice-President Finance and Chief Financial Officer at (403) 216-3920 or by e-mail at: firstname.lastname@example.org or visit our website at www.totalenergy.ca. The TSX has neither approved nor disapproved of the information contained herein
Synalloy Corporation (Nasdaq: SYNL) ("Synalloy" or the "Company"), an industrials company focused on the production and distribution of piping, tubing and specialty chemicals, has appointed Tim Lynch as executive vice president to lead the Company’s metals segment, effective today. With this appointment, all of Synalloy’s metals subsidiaries will report directly to Lynch.
Charles River IMS has been named has been named "Best Trading Platform" in the fifth annual FinTech Breakthrough Awards program.
Workiva Inc. (NYSE:WK), the company that simplifies complex work, today announced, for the third consecutive year, it has been named a Fortune 100 Best Companies to Work For®. The Company ranked 61 on the coveted 100 Best list. In addition, Workiva was also named a 2021 Fortune Best Workplace in Technology™.
South Beach’s popular Bodega Taqueria y Tequila is spreading the taco love all over South Florida.
Results from preclinical, proof-of-concept studies were presented at the 2021 AACR Annual MeetingResults demonstrate strong potential of SOT102 to eliminate tumor cells in a target-specific mannerFirst-in-human study in gastric and pancreatic cancer patients with expected launch in early 2022 PRAGUE, Czech Republic, April 12, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, announced new preclinical data of its antibody-drug conjugate (ADC), SOT102 (formerly SO-N102), for the treatment of solid tumors in a virtual poster presentation at the 2021 American Association of Cancer Research (AACR) Annual Meeting. The data, which demonstrate that SOT102 has strong potential to eliminate CLDN18.2-expressing tumor cells in a target-specific manner, provide proof of concept for SOT102 as well as SOTIO’s proprietary ADC platform. Data highlights from the poster entitled, “SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with strong therapeutic potential in solid tumors expressing low target levels” include: SOT102 showed high specificity and binding affinity for CLDN18.2, as well as efficient tumor cell killing in vivoComplete responses were observed in all 10 patient-derived mouse xenograft models, including those for gastric, pancreatic, liver, colon and lung adenocarcinomas, independent of CLDN18.2 expression levelsSOT102 demonstrated favorable tolerability and pharmacokinetic properties, with the latter substantiated by observed half-lives in the range of eight days and 13 days in cynomolgus monkey and rat, respectivelyStability of SOT102 without significant loss of payload was demonstrated in vitro and in vivo. “Antibody-drug conjugate therapies have exhibited great promise for the future of cancer treatments, however, successes have been limited by small therapeutic windows, pharmacokinetic limitations and severe safety concerns,” said Radek Špíšek, M.D., Ph.D., chief executive officer of SOTIO. “The results from our preclinical proof-of-concept study of SOT102 not only demonstrate excellent signs of safety, tolerability and efficacy in vivo, but also molecular stability and a greatly expanded therapeutic window. These findings provide SOTIO strong rationale for proceeding with in-human studies, which we look forward to initiating in early 2022.” SOT102 is a CLDN18.2 targeting antibody-drug conjugate based on a proprietary, highly specific monoclonal antibody conjugated to a potent cytotoxic drug molecule and is being developed in collaboration with NBE-Therapeutics. IND-enabling studies of SOT102 are currently ongoing with an IND filing planned for the fourth quarter of 2021, followed by a first-in-human clinical study in patients with gastric and pancreatic cancer planned for the first half of 2022. A copy of the presentation materials can be accessed on the SOTIO website. Company contact:Media contact: Richard KapsaMichael TattoryHead of CommunicationLifeSci CommunicationsT: (+420) 224 174 448T: +1 (646) 751-4362M: (+420) 603 280 email@example.com@sotio.com About SOTIOSOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies, CAR T platform and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group. For more information, please visit the company’s website at www.sotio.com. SOTIO is a registered trademark of SOTIO a.s. in selected countries.
Eagle Crusher Co. announces new Del. and Md. distributor GT Mid Atlantic to represent the manufacturer’s full line of crushing and screening plants.
Top companies covered are Amcor Limited (Zürich, Switzerland), Ardagh Group SA (Dublin, Ireland), Ball Corporation (Broomfield, Colorado, United States), Braskem SA (São Paulo, State of São Paulo, Brazil), Caraustar Industries Incorporated (Austell, GA, United States), Cargill Incorporated (Wayzata, Minnesota, United States), Cascades Incorporated (Kingsey Falls, Canada), and other key players profiled in green packaging market research reportPune, India, April 12, 2021 (GLOBE NEWSWIRE) -- The global green packaging market size is expected to reach USD 385.34 billion by 2028 while exhibiting a CAGR of 5.3% between 2021 and 2028. This information is published by Fortune Business Insights in its latest report, titled, “Green Packaging Market, 2021-2028.” The report further observes that the market stood at USD 258.35 billion in 2020 and is likely to experience significant growth in the forthcoming years. Factors such as the increasing demand for sustainable food packaging and the rising food & beverage industry are expected to propel the demand for innovative green packaging solutions worldwide. The market reached USD 267.83 billion in 2021. High Demand for Healthcare Goods amid COVID-19 On one hand, the COVID-19 pandemic has left several economies reeling under massive pressure, on the other, the demand for healthcare supplies has witnessed significant surge across the globe. Owing to this, the market is expected to experience a mixed impact during the forecast period. Get Sample PDF Brochure with Impact of COVID19: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/green-packaging-market-105113 Market Segmentation: We have segmented the market based on type, application, and region. On the basis of type, the market is segregated into recycled content packaging, reusable packaging, and degradable packaging. Based on application, the market is divided into food & beverages, consumer products, shipping, chemicals, and others.Based on application, the food & beverage is expected to showcase exponential growth backed by the growing demand for convenience food products due to their longer shelf life and high nutritional value. Based on region, the market is categorized into North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa. What does the Report Include? The market report includes a qualitative and quantitative analysis of the market and focuses on the vital aspects such as leading companies, application, and product. The market further includes crucial insights regarding the market trends and highlights key industry developments. Additionally, the report covers several factors that have contributed to the growth of the market and consists of historical data & forecast revenue growth at global, regional and country levels by adopting several research methodologies such as SWOT analysis. List of the Leading Companies Profiled in the Global Market are: Amcor Limited (Zürich, Switzerland)Ardagh Group SA (Dublin, Ireland)Ball Corporation (Broomfield, Colorado, United States)Braskem SA (São Paulo, State of São Paulo, Brazil)Caraustar Industries Incorporated (Austell, GA, United States)Cargill Incorporated (Wayzata, Minnesota, United States)Cascades Incorporated (Kingsey Falls, Canada)Other Key Players Browse Detailed Summary of Research Report with TOC: https://www.fortunebusinessinsights.com/green-packaging-market-105113 DRIVING FACTORS Expansion of the Food & Beverage Industry to Augment Growth The increasing disposable income of the working population and the hectic lifestyle are some of the factors driving the demand for convenience food products across the globe. The growing demand for ready-to-eat products is expected to propel the demand for innovative packaging solutions. For instance, in April 2019, Amcor announced the development of a lightweight, recyclable, and high tensile strength packaging solution that aids in reduction of carbon footprint by over 64%. Therefore, the rising food and beverage sector is expected to boost the global green packaging market growth during the forecast period. REGIONAL INSIGHTS Asia-Pacific – The region stood at USD 99.46 billion in 2020 and is likely to hold the largest global green packaging market share during the forecast period. This is attributable to the abundant availability of raw materials such as cartons, boxes, and bags in the region. North America – The region is expected to showcase considerable growth backed by the presence of stringent regulations that promote the adoption of sustainable green packaging solutions in the region between 2021 and 2028. The Middle East & Africa – The market in the region is expected to experience substantial growth in the forthcoming years. This is ascribable to factors such as the growing demand for canned food products that will boost the adoption of advanced green packaging solutions in the region. COMPETITIVE LANDSCAPE The partnership between Key Players to Intensify Industry Competition The global market for green packaging comprises small, medium, and large companies striving to maintain their stronghold. These companies are partnering other companies to develop innovative packaging solutions and further expand their product portfolio. Moreover, other key players are adopting strategies such as facility expansion, collaboration, and merger and acquisition that will favor the market growth in the forthcoming years. Key Industry Development: February 2021 – ReStalk, Inc. announced its strategic partnership with Sustainable Fiber Technologies (SFT) that enables the company to use SFTs suite of IP to process hemp into biopolymers and cellulose pulp. Inquire Before Buying This Research Report: https://www.fortunebusinessinsights.com/enquiry/queries/green-packaging-market-105113 Detailed Table of Content: Introduction Research ScopeMarket SegmentationResearch MethodologyDefinitions and Assumptions Executive SummaryMarket Dynamics Market DriversMarket RestraintsMarket OpportunitiesEmerging Trends Key Insights Key Emerging Trends – For Major Countries Industry SWOT AnalysisRegulatory AnalysisRecent Industry Developments - Policies, Partnerships, New Types Launches, and Mergers & Acquisitions Qualitative Insights – Impact of COVID-19 on Global Green Packaging Market Supply Chain ChallengesSteps taken by Government/Companies to overcome this impactPotential opportunities due to COVID-19 outbreak Global Green Packaging Market Analysis, Insights and Forecast, 2017-2028 Key Findings / SummaryMarket Size Estimates and Forecast By Type (Value) Recycled Content PackagingReusable PackagingDegradable Packaging By Application (Value) Food & BeveragesConsumer ProductsShippingChemicalsOthers By Region (Value) North AmericaEuropeAsia PacificLatin AmericaMiddle East & Africa TOC Continued…! Speak to Our Expert: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/green-packaging-market-105113 Have a Look at Related Research Insights: PET Packaging Market Size, Share & Industry Analysis, By Pack Type (Bottles & Jars, Bags & Pouches, Lids, Caps & Closures, Others), By Application (Food & Beverages, Personal Care, Industrial Goods, Consumer Goods, Pharmaceuticals, Other) And Regional Forecast 2020-2027 Food Packaging Market Size, Share & COVID-19 Impact Analysis, By Materials (Glass, Metal, Paper & Paperboard, Wood, and Plastics [Polypropylene, Polyethylene, PET, and Others]), By Product (Rigid, Semi-Rigid, and Flexible) By Application (Fruits & Vegetables, Bakery & Confectionery, Dairy Products, Meat, Poultry & Seafood, Sauces, Dressings and Condiments, and Others), and Regional Forecast, 2020-2027 About Us: Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in. Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: firstname.lastname@example.org LinkedIn: https://www.linkedin.com/company/fortune-business-insights Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd Twitter: https://twitter.com/FBInsightPvtLtd
Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine.
Investigational New Drug Application Cleared Study Initiated in Australia, with U.S. Site Activations Now Planned SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced initiation of its Phase 1/2 FORGE-1 study of TPX-0131, a potent inhibitor of the anaplastic lymphoma kinase (ALK) and multiple resistant mutations of ALK. The investigational new drug (IND) application for TPX-0131 is Turning Point’s third IND to be cleared by the FDA in less than 2 years, and FORGE-1 is the company’s fourth clinical study to initiate during the same period of time. The study was initiated in Australia, with U.S. site activations now planned. “With a lack of available therapies to address a broad spectrum of ALK resistant mutations, we are encouraged by the preclinical potency for TPX-0131, particularly against the G1202R solvent front mutation which is reported to occur in more than 40% of biopsies with resistance mutations,” said Ben Solomon, M.D., principal investigator for the FORGE-1 study, a medical oncologist and group leader of the Molecular Therapeutics and Biomarkers Laboratory at the Peter MacCallum Cancer Centre in Melbourne, Australia. “In addition, TPX-0131 has been shown preclinically to penetrate the central nervous system, which is important in the treatment of patients with ALK-positive non-small cell lung cancer as the disease often progresses in the brain.” ALK alterations are estimated to be responsible for 3% to 5% of non-small cell lung cancer (NSCLC) cases annually in the U.S. and EU5 countries. In preclinical studies, TPX-0131 potently inhibits wildtype ALK and is more potent in comparison to approved ALK inhibitors against many clinically observed resistance mutations, including the G1202R solvent front mutation, L1196M gatekeeper mutation, and multiple compound mutations. In addition, TPX-0131 has shown brain tissue penetration after repeat oral dosing. “Our clinical study of TPX-0131 will begin with a Phase 1 dose finding portion in patients previously treated with up to 2 prior ALK tyrosine kinase inhibitors, a population we believe is underserved today by available therapies that are less potent against known resistant mutations of ALK,” said Mohammad Hirmand, M.D., chief medical officer of Turning Point Therapeutics. The Phase 1 dose finding portion of the FORGE-1 study will enroll patients with locally advanced or metastatic TKI-pretreated ALK-positive NSCLC. Patients with up to 2 prior ALK TKIs and 1 prior platinum-based chemotherapy will be enrolled. The study endpoints include safety and tolerability, determination of the maximum tolerated dose and/or the recommended Phase 2 dose, and objective response rate by RECIST 1.1. About Turning Point Therapeutics Inc.Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com. Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics’ drug candidate TPX-0131, the results, conduct, progress and timing of Turning Point Therapeutics’ pre-clinical studies and clinical trials and plans regarding future clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contact: Jim Mazzolajim.email@example.com
Not for Distribution to United States Newswire Services or for dissemination in the United States VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- Irving Resources Inc. (CSE:IRV; OTCQX: IRVRF) (“Irving” or the “Company”) is pleased to announce that the investment agreement (the “Investment Agreement”) entered into between Irving and Newmont Corporation (“Newmont”) in April 2019, as amended in February 2020 (please refer to the Company’s news releases dated April 23, 2019 and February 20, 2020) has been amended such that the additional private placement which Newmont has the right to require the Company to undertake (the “First Additional Private Placement”) is now in the amount of US$6,000,000. In addition, Newmont has the right to require the Company to undertake a second additional private placement, also in the amount of US$6,000,000. Irving also reports that Newmont has given notice of exercise of its right to proceed with the First Additional Private Placement in the amount of US$6,000,000. These funds will be raised by the issuance of common shares of the Company at a price equal to the volume-weighted average trading price for the 30 trading days immediately preceding the date of Newmont giving its exercise notice. The funds from this private placement will be allocated as to US$5,400,000 towards exploration on the Company’s Omu project in Hokkaido, Japan and US$600,000 towards the alliance formed between Irving and an affiliate of Newmont to identify and, if designated by Newmont’s affiliate, jointly exploit mineral exploration opportunities throughout Japan. About Irving Resources Inc.: Irving is a junior exploration company with a focus on gold in Japan. Irving also holds, through a subsidiary, a Project Venture Agreement with Japan Oil, Gas and Metals National Corporation (JOGMEC). JOGMEC is a government organization established under the law of Japan, administrated by the Ministry of Economy, Trade and Industry of Japan, and is responsible for stable supply of various resources to Japan through the discovery of sizable economic deposits of base, precious and rare metals. Additional information can be found on the Company’s website: www.IRVresources.com. Akiko Levinson, President, CEO & Director THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE. Forward-looking informationSome statements in this news release may contain forward-looking information within the meaning of Canadian securities legislation including, without limitation, statements as to the expected completion of the First Additional Private Placement and use of the proceeds therefrom. Forward-looking statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements and in this news release include, without limitation, as to the intended use of proceeds from the current private placement. Such factors include, without limitation, completion of the First Additional Private Placement as well as customary risks of the mineral resource exploration industry. This news release does not constitute an offer for sale, or a solicitation of an offer to buy, in the United States or to any “U.S Person” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “1933 Act”)) of any securities of Irving. The securities of Irving have not been, and will not be, registered under the 1933 Act or under any state securities laws and may not be offered or sold in the United States or to a U.S. Person absent registration under the 1933 Act and applicable state securities laws or an applicable exemption therefrom. CONTACT: For further information, please contact: Tel: (604) 682-3234 Toll free: 1 (888) 242-3234 Fax: (604) 971-0209 info@IRVresources.com
EDMONTON, Alberta, April 12, 2021 (GLOBE NEWSWIRE) -- Nabati Foods Inc. (“Nabati'' or the “Company”), a plant-based food tech company offering whole, natural, plant-based foods for health-conscious consumers, is proud to announce that its Nabati Cheeze product will be available at Mucho Burrito locations across Canada for a limited time starting today. Mucho Burrito, Fresh Mexican Grill, is Canada’s largest chain of premium fast-casual Mexican restaurants. Mucho Burrito only serves food that is mucho real and mucho fresh, made by hand, right in front of customers’ eyes, using only the freshest ingredients, free of artificial flavours and preservatives. Mucho Burrito has over 140 locations across Canada. “Nabati Foods is pleased to continue building on our momentum in the foodservice industry by partnering with another major Canadian company,” said Nabati CEO, Ahmad Yehya. “Mucho Burrito shares Nabati’s commitment to sustainable, and flexible menu options, and we are excited to work together to feed the growing consumer demand for plant-based food.” Nabati’s plant-based cheeze product is growing quickly in popularity in the foodservice industry because it is made with simple ingredients that are not heavily processed, and it tastes and melts just like traditional dairy cheese. Based in Edmonton, Nabati offers unique dairy, meat, and cheese alternatives. All its food products are non-GMO, kosher, free of common allergens and made without refined sugar, dairy, eggs, and gluten. “Nabati Cheeze is a versatile product that can be incorporated into a wide variety of diets and many different types of recipes. We created our cheeze product because we believe that eating plant-based should not mean sacrificing taste and a great experience,” Yehya added. “This new partnership with Mucho Burrito follows our recent success partnering with COBS Bread, demonstrating the increasing popularity of Nabati Foods.” Find Nabati products locally at https://www.nabati.ca/a/store-locator Find your local Mucho Burrito at https://locations.muchoburrito.com/ About Nabati foods Inc. Nabati Foods Inc. (“Nabati”) is a family-owned food tech company offering whole, natural, plant-based, gluten and soy-free foods for health-conscious consumers. The company was founded in 2014 and has four signature product lines including dairy-free cheesecakes, cheese alternatives, and plant-based meats. Nabati products are distributed in Canada and the U.S. through grocery, foodservice, and industrial channels. Find Nabati on Social Media: on Instagram, Facebook, Twitter and LinkedIn For media inquiries, please contact: Brittany@Exvera.com For investment inquiries please contact: firstname.lastname@example.org For further information, please contact: Ahmad Yehya at email@example.com Disclosure and Caution This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the ability to complete the financing, the ability to satisfy the conditions required and approvals needed to complete the transaction, availability of funds and the results of financing efforts, - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Record Total Volumes Expected for Dollars Processed; to Exceed $1.8 Billion, Doubling of Fourth Quarter of 2020, Previous Record Quarter of $920 Million Strong Business Momentum Sustained SAN ANTONIO, April 12, 2021 (GLOBE NEWSWIRE) -- Usio, Inc. (Nasdaq: USIO), an integrated electronic payment solutions provider, today announced that it expects to report record processing results for the first quarter of 2021. Louis Hoch, President and Chief Executive Officer of Usio, said, “I am pleased to report that through our diverse payment channel strategy, all three of our segments, ACH, Card and Prepaid, are expected to report over 100% year-over-year growth in important Key Performance Metrics. This generated all-time record quarterly volume for dollars processed for the first three months of 2021. This is an excellent start to a year in which we expect to see revenue growth of 50% and a significant improvement in our profitability metrics.” These results are based in part on preliminary results. Usio plans to release final transaction and processing volume results for the first quarter at a later date. About Usio, Inc.Usio, Inc. (Nasdaq: USIO), a leading FinTech and integrated payment solutions provider, offers a wide range of payment solutions to merchants, billers, banks, service bureaus, leading FinTech and non-bank lenders, and card issuers. The Company operates credit, debit/prepaid, and ACH payment processing platforms to deliver convenient, world-class payment solutions and services to its clients. The strength of the Company is its ability to provide tailored solutions for card issuance, payment acceptance, and bill payments as well as its unique technology in the prepaid sector and its ability to provide and execute on its service commitments. Usio is headquartered in San Antonio, Texas, and has offices in Austin, Texas, and Franklin, Tennessee, just outside of Nashville. Websites: www.usio.com, www.singularpayments.com, www.payfacinabox.com, www.akimbocard.com and www.usiooutput.com. FORWARD-LOOKING STATEMENTS DISCLAIMER Except for the historical information contained herein, the matters discussed in this release include forward-looking statements which are covered by safe harbors. Those statements include, but may not be limited to, all statements regarding management's intent, belief and expectations, such as statements concerning our future and our operating and growth strategy. These forward-looking statements are identified by the use of words such as "believe," "intend," "look forward," "anticipate," "schedule,” and "expect" among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including risks related to the COVID-19 pandemic and its effect on the economy, risks related to the realization of the anticipated opportunities from the IMS acquisition, the management of the Company's growth, the loss of key resellers, the relationships with the Automated Clearinghouse network, bank sponsors, third-party card processing providers and merchants, the security of our software, hardware and information, the volatility of the stock price, the need to obtain additional financing, risks associated with new tax legislation, and compliance with complex federal, state and local laws and regulations, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its annual report on Form 10-K for the fiscal year ended December 31, 2020. One or more of these factors have affected, and in the future, could affect the Company’s businesses and financial results in the future and could cause actual results to differ materially from plans and projections. The Company believes that the assumptions underlying the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that the objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available to management. The Company assumes no obligation to update any forward-looking statements, except as required by law. Contact:Joe Hassett, Investor Relationsjoeh@gregoryfca.com484-686-6600
ZoomInfo (NASDAQ:ZI), a global leader in go-to-market intelligence solutions, today announced that it will publish financial results for the first quarter 2021 following the close of U.S. financial markets on Monday, May 3, 2021. The news release and any accompanying materials will be posted to the Investor Relations portion of ZoomInfo’s website at https://ir.zoominfo.com/.
NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Jun Group, a mobile advertising platform that delivers connected TV, audio, full-screen video and rich media campaigns for Fortune 500 advertisers, has launched its new self-service advertising platform for small and midsize businesses called Business+. Business+ makes it easy for companies to access the most impactful online advertising inventory through a simple and intuitive user interface. “Companies everywhere are looking for concrete digital solutions that can be tied directly to sales,” according to Jun Group CEO Corey Weiner. “The past decade has seen an explosion of effective digital channels that, frankly, most companies aren’t using effectively. Channels like connected TV, streaming audio and mobile in-app advertising aren’t marketed the same way as their shinier Facebook and Google counterparts.” To launch a new campaign, users simply select the type of campaign they want to run; choose their target audience by location, demographics and interest; and upload their creative. For customers without creative, Jun Group’s in-house creative team will work with existing materials or start from scratch to create an ad that gets noticed and gets results. Once the campaign is live, Business+ provides real-time updates on how the campaign is performing. “For the first time in history, everyone has access to the same inventory used by Fortune 500 companies,” says Jun Group Director of Product Management Laura Schaffer. “Business+ gives unrestricted access to these channels that are designed to reach your target audience and drive sales.” JUN GROUP Imagine advertising only to people who say they’re interested. Jun Group does this at scale, crafting custom audiences using first-party data collected directly from its SDK. Jun Group delivers full-screen video, display and rich media campaigns for Fortune 500 advertisers and drives opt-in page views for leading publishers. Jun Group is powered by its machine-learning optimization tool, Vera; its custom audience targeting platform, Schema; and its in-house creative studio, Candor. Across brand, shopper, publisher and influencer marketing, Jun Group delivers measurable results by engaging customers in a meaningful, non-intrusive way. Based in New York City, Jun Group is a division of Advantage Solutions, a leading provider of technology-enabled sales and marketing solutions. Jun Group is a certified 2020 Great Place to Work. Visit jungroup.com or follow on Linkedin. ContactWILL BRAITHWAITE | MARKETING MANAGERJUN GROUP | DIRECT firstname.lastname@example.org